Abu Dhabi has achieved a new global milestone, becoming the first in the world to administer Camizestrant, a next-generation innovative treatment for advanced breast cancer that aims to support earlier and more precise therapeutic intervention for patients who have developed resistance to conventional hormonal therapies.
This achievement reflects Abu Dhabi's standing as a leading healthcare destination, where advanced diagnostics and rapid access to specialist treatments contribute to more personalised care that is better suited to patients' needs.
Under the supervision of the Department of Health – Abu Dhabi, Burjeel Cancer Institute in Abu Dhabi administered this innovative treatment to a patient in her 40s who was diagnosed with advanced breast cancer. Examinations revealed that the patient had a mutation in the ESR1 gene, a mutation that can cause cancer to develop resistance to conventional hormonal therapies and contribute to disease progression.
Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: "The future of healthcare is not limited to treating disease after it appears, but depends on the ability to anticipate it and intervene early before it progresses.
"The world-first administration of Camizestrant in Abu Dhabi embodies the emirate's vision of building one of the most intelligent and advanced health systems, one grounded in prevention, detection and early intervention, and harnessing the latest innovations to enable patients to access advanced treatments with tangible impact at the right time, through the integration of advanced diagnostics, precision medicine and innovative therapies."
Professor Humaid bin Harmal Al Shamsi, Chief Executive Officer of Burjeel Cancer Institute, added: "We are proud at the Institute to be the first centre in the world to deliver this innovative treatment within clinical practice.
"This achievement reflects the Institute's vision of integrating advanced molecular diagnostics, artificial intelligence and modern analytical technologies into patient care pathways, enabling more precise and personalised treatment decisions based on the biological characteristics of each case."